Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.

Cavalli, F.; Beer, M; Martz, G; Jungi, W. F.; Alberto, P.; Obrecht, J.P.; Mermillod, Bernadette; Brunner, K. W.

doi:10.1136/bmj.286.6358.5

Cited by 69 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The weak regimen I (Imfp) resulted in fewer CRs than did the two other combinations, as was also the case for the PRs [19,20], The Adriamycin-containing combina tion was the most effective one in premenopausal women, whereas LMP/FVP produced the highest per centage of complete remissions in postmenopausal patients.…”

Section: Discussionmentioning

confidence: 91%

Complete Remission following Endocrine or Combined Cytotoxic and Hormonal Treatment in Advanced Breast Cancer

et al. 1987

View full text Add to dashboard Cite

Among 422 patients with advanced breast cancer treated in a randomized trial we observed 60 complete responses (CR). Sixteen were achieved among 206 patients treated with endocrine therapy alone and 37 among 216 patients treated with concomitant chemotherapy and endocrine therapy. The incidence of CR in women treated with the concomitant modality was higher in those with dominant soft tissue disease, intermediate in those with osseous or pulmonary involvement, and low in patients with liver metastases. Bone was shown to be the organ most responsive to therapy among patients treated with hormonotherapy, while patients with soft tissue metastases had an unexpectedly low rate of complete remission with this modality. The probability of achieving a CR was inversely proportional to the tumor burden in the patients treated with concomitant chemotherapy and endocrine therapy. For complete responders on hormone treatment alone and for those on combined endocrine and cytotoxic therapy, both median time to progression (26 and 29 months, respectively) and survival (52 and 53 months, respectively) were similar and statistically significantly longer than in partial or minor responders. This observation leads us to the conclusion that the hormonal component is the determinant for the length of a CR.

show abstract

Section: Discussionmentioning

confidence: 91%

Complete Remission following Endocrine or Combined Cytotoxic and Hormonal Treatment in Advanced Breast Cancer

et al. 1987

View full text Add to dashboard Cite

show abstract

“…Stratification factors included the history of previous adjuvant chemotherapy and risk category, in a modified version of that used by Cavalli et al [11]. Risk categories were defined as follows: (a) interval from initial radical surgery to first recurrence [5 years with only osseous or locoregional metastases, (b) interval from initial radical surgery to first recurrence 1-5 years and absence of visceral metastases and (c) all others.…”

Section: Treatment Planmentioning

confidence: 99%

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

Fountzilas

Dafni

Dimopoulos

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…However preclinical data suggest that chemotherapy in AIPC cell lines is more effective if given sequentially rather than concurrently (Tang et al, 2006). Additionally, in breast cancer, sequential hormone therapy and chemotherapy might be advantageous (Cavalli et al, 1983;Kim et al, 2005).…”

mentioning

confidence: 99%

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer

et al. 2008

View full text Add to dashboard Cite

When chemotherapy is used in androgen-independent prostate cancer (AIPC), androgen deprivation is continued despite its failure. In this study, we investigated whether it was possible to re-induce hormone sensitivity in previously castrate patients by stopping endocrine therapy during chemotherapy. A phase II prospective study investigated the effects of reintroduction of endocrine therapy after oral chemotherapy in 56 patients with AIPC, which was given without concurrent androgen deprivation. After chemotherapy, patients were given maximum androgen blockade until failure when treatment was switched to diethylstilbestrol and dexamethasone. Patients had already received these endocrine treatments in the same sequence before chemotherapy. All patients were castrate at the start of chemotherapy. Forty-three subsequently restarted endocrine therapy after the completion of chemotherapy. The median overall survival for these 43 patients from the time of restarting endocrine therapy was 7.7 months (95% confidence interval (CI): 3.7 -10.9 months). Sixteen (37%) patients had a 50% PSA response to treatment, which was associated with improved overall survival (14.0 months vs 3.7 months P ¼ 0.003). Eight out of 12 patients who did not respond to diethylstilbestrol before chemotherapy did so post chemotherapy. Re-induction of hormone sensitivity can occur after chemotherapy in AIPC.

show abstract

Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.

Cited by 69 publications

References 10 publications

Complete Remission following Endocrine or Combined Cytotoxic and Hormonal Treatment in Advanced Breast Cancer

Complete Remission following Endocrine or Combined Cytotoxic and Hormonal Treatment in Advanced Breast Cancer

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer

Contact Info

Product

Resources

About